In conclusion, our investigation has identified a targetable miR-181a/PPFIA1/PARP1/NF-κB-P65/KIT regulatory axis that modulates KIT expression in CML. Here, PPFIA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.